Serotonin (5-hydroxytryptamine; 5-HT) is essential for a number of central nervous system processes including the modulation of mood, perception and anxiety, the regulation of feeding behavior and the control of sleep and wakefulness. To mediate this large number of processes, multiple (>14) 5-HT receptors divided into 7 main families have evolved. This grant focuses on the 5-HT2-family of receptors, which is involved in regulating perception, appetite, anxiety, mood and cardiac development. These studies are of clinical significance because activation of 5-HT2A receptors is responsible for the actions of hallucinogens (e.g. LSD, psilocybin, mescaline) while 5-HT2B activation is involved in the cardiac side-effects of fenfluramine and related compounds (e.g. Redux, Phen/Fen) and 5-HT2C activation is important for the anorectic actions of fenfluramine. By contrast, many atypical antipsychotic and antidepressant drugs are high affinity antagonists for 5-HT2A and 5-HT2C receptors Understanding the molecular and atomic mechanisms responsible for these unique actions could lead to novel pharamacotherapies for a number of diseases including schizophrenia, depression, anxiety and feeding disorders (anorexia, bulimia) and cardiac valvulopathies. In the first specific aim, we will clarify the atomic and molecular mechanisms responsible for subtype-selective activation of 5-HT2-family receptors. The second and third specific aims will determine the relevance of conserved features of 5-HT2-family receptors for receptor-G protein activation. The fourth specific aim will determine the molecular features responsible for 5-HT2A/Gq interactions while the fifth specific aim will uncover the molecular features of Gq responsible for interacting with the 5-HT2A receptors. Novel techniques of protein biochemistry (hydroxyl-mediated 1H/2H exchange), cell biology (yeast 2-hybrid screening) and spectroscopy (FRET/BRET) will be used to arrive at testable models for 5-HT2A-Gq interactions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH057635-12
Application #
6998953
Study Section
Special Emphasis Panel (ZRG1-SSS-Q (01))
Program Officer
Nadler, Laurie S
Project Start
1994-07-01
Project End
2006-07-16
Budget Start
2005-12-01
Budget End
2006-07-16
Support Year
12
Fiscal Year
2006
Total Cost
$115,527
Indirect Cost
Name
Case Western Reserve University
Department
Biochemistry
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Davies, Marilyn A; Conley, Yvette; Roth, Bryan L (2011) Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol Res Nurs 13:55-60
Jensen, Niels H; Rodriguiz, Ramona M; Caron, Marc G et al. (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-12
Dewkar, Gajanan K; Peddi, Srinivas; Mosier, Philip D et al. (2008) Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett 18:5268-71
Dukat, Malgorzata; Mosier, Philip D; Kolanos, Renata et al. (2008) Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J Med Chem 51:603-11
Allen, John A; Yadav, Prem N; Roth, Bryan L (2008) Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacology 55:961-8
Gray, John A; Roth, Bryan L (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33:1100-19
Armbruster, Blaine N; Li, Xiang; Pausch, Mark H et al. (2007) Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A 104:5163-8
Davies, M A; Setola, V; Strachan, R T et al. (2006) Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 6:42-51
Roth, Bryan L; Kroeze, Wesley K (2006) Screening the receptorome yields validated molecular targets for drug discovery. Curr Pharm Des 12:1785-95
Strachan, Ryan T; Ferrara, Gina; Roth, Bryan L (2006) Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today 11:708-16

Showing the most recent 10 out of 37 publications